News & Events
Published On: 10/12/2017
Bristol-Myers Squibb (BMY) Extends Strategic Partnership with TARGET PharmaSolutions for TARGET-NASH
CHAPEL HILL, N.C, Oct. 12, 2017 /PRNewswire/ -- TARGET PharmaSolutions, Inc., a real-world clinical data company, is pleased to announce that Bristol-Myers Squibb (BMY) has extended its strategic partnership for TARGET-NASH to a multi-year agreement. Bristol-Myers Squibb is committed to the discovery and development of medicines for fibrosis, including NASH.
TARGET-NASH is a longitudinal observational study that evaluates patients with nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH). TARGET-NASH is collecting retrospective and prospective data on its enrolled patients and is developing a biorepository which its stakeholders can access for translational studies (including those of genomics and biomarkers). To date, TARGET-NASH has enrolled over 2,364 patients at 55 sites. There have been multiple presentations on TARGET-NASH at leading academic conferences and a methodology publication is currently in press. TARGET-NASH will enroll up to 15,000 patients over the coming years. TARGET-NASH is led by an academic steering committee chaired by Drs. Arun Sanyal, MD (Virginia Commonwealth University); Ken Cusi, MD (University of Florida), and Brent Tetri (St. Louis University).
Meg Powell, CEO of TARGET PharmaSolutions, stated "We are pleased to extend our partnership with Bristol-Myers Squibb for TARGET-NASH. We believe this is a testament to the long-term value the TARGET model generates for our industry partners throughout the development and commercialization process, including benefits for Research, Clinical, Regulatory, Medical Affairs, Commercialization, Marketing, Health Economics and Outcomes groups."
TARGET PharmaSolutions provides insights and actions to improve clinical, medical, and commercial outcomes throughout the pharmaceutical development and commercialization process. The TARGET model organizes a community of stakeholders, including pharmaceutical manufacturers, key opinion leaders, regulatory agencies, and patient advocacy groups, around a specific disease to generate real world evidence about the natural history of the given disease, current treatment paradigm, and patient outcomes. This model enables TARGET's stakeholders to answer critical strategic and planning questions and to fulfill regulatory and payer requests. The TARGET model also provides access to a biorepository linked to validated clinical outcomes, including patient reported outcomes (PROs).
TARGET PharmaSolutions was formed in February, 2015 and has four disease communities: TARGET-NASH (nonalcoholic steatohepatitis), TARGET-PBC (primary biliary cholangitis), TARGET-HCC (hepatocellular carcinoma), and TARGET-IBD (inflammatory bowel disease). The TARGET model is based on the success of HCV-TARGET, a case study in Hepatitis C. Formed in 2011 by Drs. Michael Fried, MD (University of North Carolina) and David Nelson, MD (University of Florida), HCV-TARGET has enrolled over 11,000 patients and has generated data that has been used by physicians, payers, and regulatory agencies around the world.
About Target RWE
Headquartered in Durham, NC, Target RWE is an innovative health evidence solutions company generating real-world evidence (RWE) and delivering regulatory-grade data to partners to advance clinical, medical, and commercial outcomes as well as to improve patient health guidelines and quality of care.
Target RWE has developed a turnkey health evidence solution which rapidly aggregates real-world data (RWD) from a large network of participating sites (academic and community) across the United States, Europe and other non-U.S. locations. Target RWE’s datasets are aggregated from various data sources including registries, electronic medical records, patient outcomes measures, biospecimen analyses, and claims databases. Whether partners need consulting services, datasets, support for custom solutions or access to a large biorepository of disease agnostic patient samples, Target RWE strives to be the preferred choice.
For more information, visit www.targetrwe.com.
984.234.0268 ext 205
01/15/2021Target RWE Acquires NoviSci Inc., Adding Significant Analytical Capabilities to Leading Real-World Evidence Platform
12/21/2020TARGET-HCC Initial Manuscript Published in Hepatology Communications
12/18/2020Target RWE Virtual Posters at Annual AIBD, RAD Conferences
11/28/2020TARGET-DERM Objectives Published in BMJ Open
11/13/2020Target RWE Data Presented at AASLD Virtual Meeting Provides Important Updates for NASH and PBC Communities